GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

FTSE 100 fluctuates after key US inflation report as the pound remains below $1.31 ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

The pharmaceutical giant has agreed to a $2.2bn (£1.68bn) settlement to resolve lawsuits in the US alleging that the ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...

Sanofi is nearing the sale of its consumer health business to Clayton Dubilier & Rice, a year after Chief Executive Officer Paul Hudson announced plans to split off the division to concentrate on ...

The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...

GSK PLC on Wednesday said it reached two confidential settlements regarding the Zantac case in California State Court. The London-based pharmaceutical company said the cases concerned John Russell ...

When UK Prime Minister Keir Starmer welcomes business leaders to a major investment summit in London on Monday, his message to executives from the likes of BlackRock, Vodafone and GSK will be simple: ...

The business tycoon led Tata Group, one of India's largest companies, for more than 20 years. In his time as chairman, the ...